Health TrialsbyHealthPanel

Replacing Bone Marrow Diagnostics With Peripheral Blood Analysis in MPN Patients

ConditionMyeloproliferative Neoplasm
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorWeizmann Institute of Science

About this trial

The PERIBLOOD-MPN study aims to develop and validate a minimally invasive peripheral blood test using single-cell RNA sequencing to accurately diagnose and classify myeloproliferative neoplasms, potentially reducing the need for invasive bone marrow biopsies.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age ≥ 18 years

Elevated hemoglobin (>16.5 g/dL for men, >16.0 g/dL for women), hematocrit (>49% for men, >48% for women), or increased red cell mass

Bone marrow biopsy showing hypercellularity with trilineage growth (panmyelosis)

Presence of JAK2 mutation (V617F or exon 12)

Disqualifiers

Patients diagnosed with MPN receiving therapy

Patients who have undergone a bone marrow transplant

Trial population

Patients with MPN, or suspicion for MPN, who are referred to BM will be recruited to the study

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • PERIBLOOD-MPN

    Diagnostic test

    Observational intervation of cHSPCs

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

1

To development PERIBLOOD-MPN Diagnostic Test

Development of PERIBLOOD-MPN Diagnostic Test Using PB-Derived CD34+ cHSPCs for Diagnosis of MPN

Time frame
Three months following the PB sample

Secondary outcomes

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Weizmann Institute of Science

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: